IRB #

STUDY00017126

Title

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma

Principal Investigator

Gary Takahashi

Study Purpose

The purpose of this study is to compare the effects of ibrutinib plus rituximab with placebo plus rituximab on participants with Follicular Lymphoma.

Medical Condition(s)

Treatment Naive Follicular Lymphoma

Eligibility Criteria

60 Years and older
No prior treatment for Follicular Lymphoma

Age Range

60 - 120

Healthy Volunteers Needed

No

Duration of Participation

If eligible you will receive the study treatment until your disease worsens or you have bad side effects.

Minors Included

No

Contact

Knight Cancer Institute Clinical Trials
trials@ohsu.edu
503 494-1080

Sponsor

Pharmacyclics LLC.

Recruitment End

10/30/2020

Compensation Provided

No


Go Back